Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2008

01-02-2008 | Commentary

Effect of sepsis therapies on health-related quality of life

Authors: Sara E Erickson, Greg S Martin

Published in: Critical Care | Issue 1/2008

Login to get access

Abstract

Sepsis is one of the most common conditions encountered in the intensive care unit and is the 10th leading cause of death overall in the United States. Both long-term survival and health-related quality of life are reduced in survivors of sepsis, yet there is little knowledge of the effect of sepsis-specific interventions on either long-term survival or health-related quality of life. The present article discusses the importance of studying health-related quality of life as it relates to sepsis management strategies, particularly in the context of pharmacologic therapy with recombinant human activated protein C.
Literature
1.
Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG: A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care. Crit Care 2007, 11: R128. 10.1186/cc6195PubMedCentralCrossRefPubMed
2.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002CrossRefPubMed
3.
Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348: 1546-1554. 10.1056/NEJMoa022139CrossRefPubMed
4.
Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K: Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003, 31: 2332-2338. 10.1097/01.CCM.0000085141.75513.2BCrossRefPubMed
5.
Quartin AA, Schein RM, Kett DH, Peduzzi PN: Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997, 277: 1058-1063. 10.1001/jama.277.13.1058CrossRefPubMed
6.
Perl TM, Dvorak L, Hwang T, Wenzel RP: Long-term survival and function after suspected gram-negative sepsis. JAMA 1995, 274: 338-345. 10.1001/jama.274.4.338CrossRefPubMed
7.
Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA: Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28: 3599-3605. 10.1097/00003246-200011000-00006CrossRefPubMed
8.
Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004, 32: 2199-2206. 10.1097/01.CCM.0000114816.62331.08CrossRefPubMed
9.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
10.
Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31: 12-19. 10.1097/00003246-200301000-00002CrossRefPubMed
11.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 10.1056/NEJMoa050935CrossRefPubMed
12.
Friedrich JO, Adhikari NK, Meade MO: Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit Care 2006, 10: 145. 10.1186/cc4947PubMedCentralCrossRefPubMed
13.
Mrus JM, Braun L, Yi MS, Linde-Zwirble WT, Johnston JA: Impact of HIV/AIDS on care and outcomes of severe sepsis. Crit Care 2005, 9: R623-R630. 10.1186/cc3811PubMedCentralCrossRefPubMed
14.
Danai PA, Moss M, Mannino DM, Martin GS: The epidemiology of sepsis in patients with malignancy. Chest 2006, 129: 1432-1440. 10.1378/chest.129.6.1432CrossRefPubMed
15.
Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM, Martin GS: The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med 2006, 34: 2576-2582. 10.1097/01.CCM.0000239114.50519.0EPubMedCentralCrossRefPubMed
Metadata
Title
Effect of sepsis therapies on health-related quality of life
Authors
Sara E Erickson
Greg S Martin
Publication date
01-02-2008
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2008
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6215

Other articles of this Issue 1/2008

Critical Care 1/2008 Go to the issue

Research

Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage

Research

Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia

Research

Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data

Research

Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection

Letter

Extrapulmonary effects of nitric oxide inhalation therapy: time to consider new dosing regimes?

Research

Glycemic penalty index for adequately assessing and comparing different blood glucose control algorithms